MCL1 and diffuse large B-cell lymphoma: In translation, all BCL2-negative malignancies (e.g., Burkitt lymphoma, BCL2-negative DLBCL, or a substantial part of MM) are inherently “resistant” to BCL2 inhibition with venetoclax but still may be effectively targeted with other BH3 mimetics, e.g., MCL1 inhibitors.